See full summit details here.
Over the past year, the allogeneic cell therapy landscape has continued to evolve. Amidst the clinical and commercial developments, the challenging reality of increased demand for donors and high quality starting material is thrust into the spotlight.
As such, there is no better time to join industry leaders for the inaugural Donor Selection and Cell Source Summit (November 28-30, San Francisco, CA), the first and only industry focused forum solely dedicated to establishing gold standard donor screening strategies and best-in class cell source starting materials to drive scalability and spearhead successful clinical outcomes.
The timely arrival of this exciting new conference will unite biopharma and academics to advance knowledge on donor selection, management, and sustainability to ensure a consistent and reliable supply of cell source material required for clinical trials and beyond.
The speaker faculty includes:
Stacey Cranert,Director, Immunoncology, Poseida Therapeutics
Jesse Cotari, CSO & Co-Founder,ImmuneBridge
Amanda Conerty,Executive Director, Process, Analytical Development & Manufacturing, Artiva Biotherapeutics
Allen Feng, CSO,HebeCell
Colleen Delaney, CEO, Deverra Therapeutics
Ying He, Director, Process & Development, Allogene
Check out the official program here for full session details.
Don’t forget to register while spots remain!
The post Hear from Allogene, Poseida Therapeutics, Caribou Bio and more! appeared first on Pharma Journalist.
